BioSpace News Archive

Artelo Biosciences, Inc. today announced that it will be participating in the 2024 Pharma Partnering Summit being held May 14th – 15th in San Diego, California.

Medtech Canada is very pleased to welcome James Brodie of Johnson & Johnson MedTech as Chair of the Medtech Canada Board of Directors.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment...

Flightpath Biosciences Inc. announced today that the first healthy volunteer participants have been dosed in its Phase I clinical trial of FP-100 (hygromycin A), an orally-available, narrow-spectrum antimicrobial drug candidate.

Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, presented results from new preclinical research demonstrating production of active ALP by a BCM, which highlights BCMs as a potential treatment for Hypophosphatasia.

Nika Pharmaceuticals, Inc. announces that it is the beneficial owner of a production building and land valued at $2,045,209, located in Sofia Province, Bulgaria.

The San Francisco Business Times has named Gladstone Institutes President Deepak Srivastava, MD, as one of the Most Admired CEOs among Bay Area businesses and nonprofits.

Bayer will present Kerendia® data from its comprehensive clinical trial program in patients with chronic kidney disease and type 2 diabetes in addition to data from FINEARTS-HF at Heart Failure 2024, a scientific congress of the European Society of Cardiology, taking place May 11-14, 2024 in Lisbon, Portugal.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024.